Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3OTHER_GOV 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Gastrointestinal 2Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 121Melanoma 111Neoplasms 66Carcinoma, Renal Cell 60Colorectal Neoplasms 43Neoplasm Metastasis 39Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 35Carcinoma, Hepatocellular 33Carcinoma, Transitional Cell 27Lung Neoplasms 23Pancreatic Neoplasms 22Triple Negative Breast Neoplasms 21Ovarian Neoplasms 21Head and Neck Neoplasms 21Advanced Cancer 19Breast Neoplasms 17Urinary Bladder Neoplasms 15Small Cell Lung Carcinoma 14Kidney Neoplasms 13Recurrence 11Hodgkin Disease 11Uterine Cervical Neoplasms 10Skin Neoplasms 10Lymphoma 10Solid Tumor 9Mesothelioma 9Endometrial Neoplasms 9Carcinoma, Merkel Cell 9Carcinoma 9

Interventions

Ipilimumab 9pembrolizumab 6Nivolumab 4tremelimumab 3Paclitaxel 3Carboplatin 3spartalizumab 2lenvatinib 2durvalumab 2Doxorubicin 2Bevacizumab 2trastuzumab deruxtecan 1tilsotolimod 1tebentafusp 1osimertinib 1eribulin 1envafolimab 1cemiplimab 1balstilimab 1Vemurafenib 1Vascular Endothelial Growth Factor A 1Standard of Care 1Pemetrexed 1Oxaliplatin 1Docetaxel 1Cisplatin 1Capecitabine 1Axitinib 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Diabetes Mellitus, Insulin-Dependent, 12 × Nivolumab × Clear all
NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Biocon Limited

Phase 1 Not yet recruiting
120 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT07000149 2026-03-10

eVOLVE-RCC02

AstraZeneca

Phase 3 Active not recruiting
1,116 enrolled
Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT03639714 2023-09-13

A Study of a Personalized Neoantigen Cancer Vaccine

Gritstone bio, Inc.

Phase 1/2 Completed
29 enrolled
GastrointestinalGenitourinaryThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms

NCT03953235 2023-09-13

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Gritstone bio, Inc.

Phase 1/2 Completed
39 enrolled
GastrointestinalThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡